Stay updated on PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now displays a new revision label: Revision: v3.4.2. This is a minor meta-update and does not alter study details or eligibility information.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision: v3.4.1 added and v3.4.0 removed; this appears to be an internal version update with no changes to the page content or study information.SummaryDifference0.1%

- Check28 days agoChange DetectedA glossary toggle was added and QC/version metadata was updated (Last Update Submitted that Met QC Criteria and Revision: v3.4.0); FEAR Act data labeling was adjusted.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision v3.3.4 was added and Revision v3.3.3 was removed; this is a routine page update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedThe study's location information was reorganized: a consolidated 'Locations' section was added, and the per-state subsections for California, Louisiana, New York, Ohio, and Texas were removed (revision v3.3.3).SummaryDifference0.7%

- Check92 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.1%

Stay in the know with updates to PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.